Brak-Biotin - Control Lysate

General information
 

Name:
Brak-Biotin - Control Lysate
Size:
20 μg
Catalog no:
X1238C
Price:
549 EUR
 

Additional extra details
 

  • Category

    Other Reagents

    Long description

    BRAK is a novel member of the CXC chemokine family. The function of BRAK in cells remains largely unknown. It was identified by translating expressed sequence tags (ESTs) derived from breast and kidney carcinoma libraries and was found to be expressed ubiquitously in RNA from normal tissue extracts but absent from a variety of established in vitro tumor cell lines.

    Antibody come from

    Hybridoma produced by the fusion of splenocytes from mice immunized with cytoskeleton preparation from HeLa cells and mouse myeloma cells.

  • Other description

    Provided as solution in phosphate buffered saline with 0.08% sodium azide.

    Clone

    not specified

    Antigen-antibody binding interaction

    Brak-Biotin - Control Lysate

  • Antibody is raised in

    see techfile

    Antibody's reacts with

    Human CXC

    Antibody's reacts with these species

    This antibody doesn't cross react with other species

  • Antibody's specificity

    No Data Available

    Application

    Activity Assay

    Antibody's suited for

    Antibody detects cytokeration protein numbers 13 and 10 (molecular weights 53 and 56.6 kDa, respectively, according to Moll's classification) by Western blot. Does not react with other cytokeratins or other proteins. Optimal concentration should be evaluated by serial dilutions.

  • Storage

    -20ºC

    Relevant references

    1. Ivanyi, D., et al. Modulation of mammary carcinoma cell phenotype and keratin expression patterns by retinoic acid. Cancer Lett, 1993, 73, 191-205._x000B__x000B_2. Ivanyi, D., et al. Cytokeratins as markers of initial stages of squamous metaplasia in feline mammary carcinomas. Am. J. Vet. Res. 1993, 54, 1095-1102._x000B__x000B_3. Ivanyi, D., et al. Patterns of expression of feline cytokeratins in healthy epithelia and mammary carcinoma cells. American Journal of Veterinary Research, 1992, 53, 304-314._x000B__x000B_4. Ivanyi, D., et al. Keratin subtypes in carcinomas of the uterine cervix: implications for histogenesis and differential diagnosis. Cancer Research, 1990, 50, 5143-5152._x000B__x000B_5. Ivanyi, D., et al. New monoclonal antibodies recognizing epidermal differentiation-associated keratins in formalin-fixed, paraffin-embedded tissue. Keratin 10 expression in carcinoma of the vulva. J of Pathol, 1989, 159, 7-12._x000B__x000B_6. Moll, R., et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31, 11-24

    Protein number

    see ncbi

  • Warnings

    This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.

    Tissue

    control

    Properties

    Biotin conjugates can be detected by horseradish peroxidase, alkaline phosphatase substrates or anti biotin conjugated antibodies. Avidin and Streptavidin bind to the small biotin and are couple to HRP or AP for ELISA. To break the streptavidin Biotin bond we suggest to use a 6 molar guanidine HCl solution with acidity of pH 1.6.

  • Conjugation

    Biotinylated

    Description

    Isotype or positive controls by peptides, antibodies and deactivated samples.